newsfilter
← Latest News
Business Wire·

Reata Pharmaceuticals, Inc. Announces First Quarter 2022 Financial Results and Provides an Update on Clinical Development Programs

Completed Rolling Submission of NDA for Omaveloxolone for Treatment of Patients with Friedreich's Ataxia; Actively Preparing for Commercial Launch Updates Outcome of Type A Meeting with the FDA on the Protocol Amendment for FALCON Reaffirms Cash R